Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients.
暂无分享,去创建一个
[1] FDA , 2019, Encyclopedia of Food and Agricultural Ethics.
[2] T. Kotsimbos,et al. Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[3] David Y. Thomas,et al. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX‐770 (ivacaftor) , 2016, British journal of pharmacology.
[4] Xiaohong Huang,et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.
[5] V. Carbone,et al. Drug–drug plasma protein binding interactions of ivacaftor , 2015, Journal of molecular recognition : JMR.
[6] Jinglan Zhou,et al. Discovery of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, ivacaftor), a potent and orally bioavailable CFTR potentiator. , 2014, Journal of medicinal chemistry.
[7] D. Holmes. False dawn for cystic fibrosis disease modifiers? , 2014, Nature Reviews Drug Discovery.
[8] G. Lukács,et al. Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression , 2014, Science Translational Medicine.
[9] N. Dokholyan,et al. Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis , 2014, Science Translational Medicine.
[10] Matthias Griese,et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. , 2011, The New England journal of medicine.
[11] P. Flume,et al. The clinical approach to lung disease in patients with cystic fibrosis. , 2009, Seminars in respiratory and critical care medicine.